QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:MOR

MorphoSys - MOR Stock Forecast, Price & News

$4.94
+0.01 (+0.20%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.90
▼
$4.98
50-Day Range
$3.21
▼
$4.93
52-Week Range
$3.17
▼
$8.26
Volume
71,917 shs
Average Volume
237,462 shs
Market Capitalization
$676.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.58

MorphoSys MarketRank™ Forecast

Analyst Rating
Hold
1.63 Rating Score
Upside/​Downside
255.9% Upside
$17.58 Price Target
Short Interest
Healthy
0.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.28mentions of MorphoSys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.88) to ($2.15) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

665th out of 1,055 stocks

Pharmaceutical Preparations Industry

336th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

MOR stock logo

About MorphoSys (NASDAQ:MOR) Stock

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

January 25, 2023 | americanbankingnews.com
MorphoSys (NASDAQ:MOR) Shares Gap Up to $4.70
January 9, 2023 | markets.businessinsider.com
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 9, 2023 | finance.yahoo.com
MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
January 7, 2023 | finance.yahoo.com
Investors in MorphoSys (ETR:MOR) have unfortunately lost 90% over the last three years
January 6, 2023 | seekingalpha.com
MorphoSys AG: Staying On The Sidelines
December 20, 2022 | uk.finance.yahoo.com
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
December 20, 2022 | markets.businessinsider.com
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 20, 2022 | msn.com
German pharma company MorphoSys's finance head to step down
December 20, 2022 | finance.yahoo.com
Myelofibrosis Market is Expected to Grow at a CAGR of 7.3% by 2032 | DelveInsight
December 10, 2022 | uk.finance.yahoo.com
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
December 6, 2022 | markets.businessinsider.com
MorphoSys, Novartis To Research & Commercialize Pre-clinical Inhibitors Of Novel Cancer Target
December 6, 2022 | uk.finance.yahoo.com
MorphoSys Out Licenses Pre-Clinical Oncology Program
November 19, 2022 | finance.yahoo.com
Earnings Release: Here's Why Analysts Cut Their MorphoSys AG (ETR:MOR) Price Target To €29.30
November 17, 2022 | seekingalpha.com
MorphoSys AG (MOR) Q3 2022 Earnings Call Transcript
November 16, 2022 | finance.yahoo.com
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
November 15, 2022 | msn.com
MorphoSys Earnings Preview
November 15, 2022 | investing.com
Stifel Downgrades MorphoSys AG to Hold
November 15, 2022 | msn.com
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022 | msn.com
Why MorphoSys Shares Are Trading Lower By Around 32%; Here Are 30 Stocks Moving Premarket
November 14, 2022 | finance.yahoo.com
Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months
November 14, 2022 | finance.yahoo.com
MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals
November 14, 2022 | markets.businessinsider.com
EQS-News: MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease
November 14, 2022 | msn.com
Roche's Alzheimer's drug fails to meet goal in long awaited trial
November 14, 2022 | ca.finance.yahoo.com
MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
November 14, 2022 | markets.businessinsider.com
EQS-Adhoc: Ad hoc: MorphoSys Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimers Disease
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Company Calendar

Last Earnings
11/16/2022
Today
1/27/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MOR
CUSIP
N/A
CIK
1340243
Web
www.morphosys.com
Phone
(498) 989-9270
Fax
49-89-8992-7222
Employees
732
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.58
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$2.90
Forecasted Upside/Downside
+255.9%
Consensus Rating
Hold
Rating Score (0-4)
1.63
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($7.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-608,660,000.00
Net Margins
-357.89%
Pretax Margin
-374.48%
Return on Equity
-1,157.24%
Return on Assets
-34.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.76
Quick Ratio
3.67

Sales & Book Value

Annual Sales
$212.49 million
Price / Sales
3.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
2.33

Miscellaneous

Outstanding Shares
136,928,000
Free Float
136,860,000
Market Cap
$676.42 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Dr. Jean-Paul Kress M.D.Dr. Jean-Paul Kress M.D. (Age 58)
    Chairman of Management Board, MD & CEO
    Comp: $2.05M
  • Mr. Sung H. LeeMr. Sung H. Lee (Age 53)
    CFO & Member of Management Board
    Comp: $518.29k
  • Dr. Marlies Sproll (Age 65)
    Special Adviser to the Chief Exec. Officer
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Ms. Lara Smith Weber
    Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn
    Sr. VP & Head of Investor Relations
  • Ms. Charlotte Lohmann (Age 53)
    Sr. VP of Legal, Compliance & IP and Gen. Counsel
  • Mr. Thomas Biegi
    VP & Head of Corp. Communications
  • Ms. Maria Castresana
    Sr. VP & Global Head of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













MOR Stock - Frequently Asked Questions

Should I buy or sell MorphoSys stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 sell ratings, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View MOR analyst ratings or view top-rated stocks.

What is MorphoSys' stock price forecast for 2023?

8 analysts have issued 12-month price targets for MorphoSys' shares. Their MOR share price forecasts range from $2.90 to $30.00. On average, they expect the company's share price to reach $17.58 in the next year. This suggests a possible upside of 254.4% from the stock's current price.
View analysts price targets for MOR or view top-rated stocks among Wall Street analysts.

How have MOR shares performed in 2023?

MorphoSys' stock was trading at $3.58 at the start of the year. Since then, MOR shares have increased by 38.5% and is now trading at $4.96.
View the best growth stocks for 2023 here.

When is MorphoSys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our MOR earnings forecast.

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) released its quarterly earnings data on Wednesday, November, 16th. The company reported ($0.91) EPS for the quarter. The business had revenue of $96.56 million for the quarter. MorphoSys had a negative trailing twelve-month return on equity of 1,157.24% and a negative net margin of 357.89%. During the same period in the prior year, the firm earned ($0.97) EPS.

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did MorphoSys IPO?

(MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $4.96.

How much money does MorphoSys make?

MorphoSys (NASDAQ:MOR) has a market capitalization of $679.16 million and generates $212.49 million in revenue each year. The company earns $-608,660,000.00 in net income (profit) each year or ($7.05) on an earnings per share basis.

How many employees does MorphoSys have?

The company employs 732 workers across the globe.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The official website for the company is www.morphosys.com. The company can be reached via phone at (498) 989-9270, via email at investors@morphosys.com, or via fax at 49-89-8992-7222.

This page (NASDAQ:MOR) was last updated on 1/27/2023 by MarketBeat.com Staff